The North American Society for Pediatric Gastroenterology Hepatology and Nutrition (NASPGHAN) guidelines recommend MASLD screening for children aged 9 to 11 who have obesity or are overweight with additional risk factors [49]
Caputi S, Trubiani O, Sinjari B, et al
Short-term use may not carry the same level of risk, emphasizing the importance of limiting duration when possible
Sanofi did combine lixisenatide with insulin glargine in a premixed pen (Soliqua), which was a novel combo product for patients needing both basal insulin and a GLP-1 RA
However, despite its effectiveness for many, some individuals may find they are not losing weight as expected
Kidney function deterioration is dependent on blood pressure levels: 11.2 year follow-up in diabetic patients